Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

391.34
Delayed Data
As of Jul 22
 +1.82 / +0.47%
Today’s Change
329.09
Today|||52-Week Range
605.93
-27.91%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$41.1B

Company Description

Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company involves in marketing medicines for eye diseases, colorectal cancer and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma and atopic dermatitis. Its products include EYLEA (aflibercept) injection, which is used for the treatment of neovascular age related macular degeneration; ARCALYST (rilonacept), which is used for the treatment of Cryopyrin-Associated Periodic Syndrome, including Familial Cold Auto-inflammatory Syndrome and Muckle-Wells Syndrome; and PRALUENT (alirocumab) Injection for treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL- C. Regeneron Pharmaceuticals was founded by Alferd G. Gilman, Leonard S. Schleifer and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Contact Information

Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown New York 10591-6707
P:(914) 847-7000
Investor Relations:
(914) 847-7799

Employees

Shareholders

Mutual fund holders47.36%
Individual stakeholders25.32%
Other institutional24.34%

Top Executives

Leonard S. SchleiferPresident, Chief Executive Officer & Director
Robert E. LandryChief Financial Officer & Senior VP-Finance
George Damis YancopoulosDirector & Chief Scientific Officer
Neil StahlExecutive VP-Research & Development
Peter PowchikSenior Vice President-Clinical Development